HC Wainwright Issues Pessimistic Outlook for AxoGen Earnings

Posted by Geri Gentry on Aug 5th, 2026

AxoGen, Inc. (NASDAQ:AXGN – Free Report) – Equities research analysts at HC Wainwright decreased their Q3 2026 earnings per share estimates for shares of AxoGen in a note issued to investors on Thursday, July 30th. HC Wainwright analyst Y. Chen now expects that the medical equipment provider will post earnings of ($0.03) per share for the quarter, down from their previous estimate of $0.02. HC Wainwright currently has a “Buy” rating and a $53.00 target price on the stock. The consensus estimate for AxoGen’s current full-year earnings is ($0.37) per share. HC Wainwright also issued estimates for AxoGen’s Q4 2026 earnings at ($0.04) EPS, FY2026 earnings at ($0.46) EPS, Q2 2027 earnings at ($0.01) EPS, Q3 2027 earnings at $0.02 EPS, Q4 2027 earnings at $0.05 EPS and FY2027 earnings at $0.03 EPS.

AxoGen (NASDAQ:AXGN – Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.12 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.12. AxoGen had a negative return on equity of 8.90% and a negative net margin of 13.36%.The company had revenue of $69.73 million for the quarter, compared to the consensus estimate of $67.10 million.

Several other research analysts have also commented on AXGN. Jefferies Financial Group reiterated a “buy” rating and set a $55.00 price objective on shares of AxoGen in a research note on Wednesday, July 29th. Citizens Jmp increased their price objective on AxoGen from $50.00 to $55.00 and gave the company a “market outperform” rating in a report on Thursday, July 30th. Truist Financial set a $55.00 target price on AxoGen in a research note on Thursday, July 30th. Weiss Ratings restated a “sell (d-)” rating on shares of AxoGen in a report on Friday, May 29th. Finally, Lake Street Capital raised their price target on shares of AxoGen from $40.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, April 23rd. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $51.00.

View Our Latest Report on AXGN

AxoGen Stock Performance

AXGN stock opened at $45.96 on Wednesday. AxoGen has a one year low of $12.75 and a one year high of $46.95. The firm has a market cap of $2.47 billion, a price-to-earnings ratio of -67.59 and a beta of 1.11. The company has a debt-to-equity ratio of 0.07, a quick ratio of 5.04 and a current ratio of 6.60. The firm has a 50-day simple moving average of $42.32 and a two-hundred day simple moving average of $37.62.

Insider Activity at AxoGen

In other news, Director Amy Mcbride Wendell sold 1,647 shares of the company’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $42.60, for a total value of $70,162.20. Following the sale, the director directly owned 93,826 shares of the company’s stock, valued at $3,996,987.60. This represents a 1.73% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director John Johnson sold 11,050 shares of the stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $43.26, for a total transaction of $478,023.00. Following the completion of the sale, the director owned 11,050 shares in the company, valued at $478,023. The trade was a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 29,041 shares of company stock worth $1,268,792 over the last quarter. Insiders own 2.44% of the company’s stock.

Institutional Investors Weigh In On AxoGen

Hedge funds have recently added to or reduced their stakes in the business. Stephens Investment Management Group LLC purchased a new position in shares of AxoGen during the 4th quarter valued at about $5,043,000. Legato Capital Management LLC purchased a new stake in shares of AxoGen in the fourth quarter worth about $1,323,000. Allspring Global Investments Holdings LLC acquired a new stake in AxoGen during the fourth quarter worth about $800,000. Westover Capital Advisors LLC acquired a new stake in AxoGen during the fourth quarter worth about $500,000. Finally, TimesSquare Capital Management LLC purchased a new position in AxoGen during the fourth quarter valued at approximately $11,025,000. 80.29% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about AxoGen

Here are the key news stories impacting AxoGen this week:

Positive Sentiment: HC Wainwright maintained its Buy rating and $53 price target, which remains above AxoGen’s recent trading level and implies further upside if the company meets the firm’s longer-term expectations.
Positive Sentiment: A separate analyst review characterized AxoGen as having an average “Moderate Buy” rating, indicating that overall Wall Street sentiment remains favorable. AxoGen Given Average Rating of Moderate Buy by Analysts
Neutral Sentiment: AxoGen’s latest quarterly results were solid relative to expectations: revenue of $69.73 million exceeded the $67.10 million consensus estimate, while EPS of $0.12 matched forecasts. However, the company remains unprofitable, with a negative net margin and analysts expecting a full-year loss.
Negative Sentiment: HC Wainwright cut its FY2026 EPS forecast to a loss of $0.46 from a loss of $0.32 and reduced its FY2027 estimate to $0.03 from $0.44. The firm also lowered estimates for several upcoming quarters, including Q3 2026 to a $0.03 loss from $0.02 earnings and Q4 2026 to a $0.04 loss from $0.04 earnings.
Negative Sentiment: Additional cuts affected Q2 2027 EPS, now estimated at a $0.01 loss versus $0.09 earnings previously, and Q3 and Q4 2027 EPS, now forecast at $0.02 and $0.05, respectively. These revisions suggest slower-than-expected profitability and may limit near-term upside despite the retained Buy rating.

AxoGen Company Profile

(Get Free Report)

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.